Mr. Stephen Lockyer reports

MEDX ANNOUNCES APPLICATION FOR EXTENSION FOR A FURTHER $300,000 OF SERIES I LOAN NOTES

In its press release dated Oct. 22, 2024, MedX Health Corp. had obtained final TSX Venture Exchange acceptance for extension of the maturity date of $2.65-million out of $3.7-million of then outstanding convertible loan notes (Series I notes) from Dec. 31, 2023, to Dec. 31, 2025 (the extension), and that it may submit request(s) to the TSX-V for acceptance in the event that additional holders of Series I notes agreed to accept the extension. The company is now pleased to announce that holders of a further $300,000 of Series I notes have agreed to the extension, and accordingly the company has made application to the TSX-V for acceptance, issuance of which is subject to all applicable TSX-V policies.

The Series I loan notes, originally issued in the first quarter of 2021, pay interest quarterly at 6 per cent per year, originally matured on Dec. 31, 2023 (original maturity date), which, where holders have agreed and TSX-V acceptance has been issued, has been extended to Dec. 31, 2025, and are convertible, at the option of the holder, into units at 14 cents per unit. Each unit comprises one fully paid common share and one-half of a share purchase warrant; each whole warrant is exercisable up until the new maturity date to acquire a further common share at 20 cents. Subject to, and conditional on acceptance by the TSX-V, the company will extend maturity date of the further $300,000 of Series I notes, and the corresponding expiration date of the underlying warrants, to Dec. 31, 2025.

About MedX Health Corp.

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its Siascopy on DermSecure telemedicine platform, utilizing its Siascopy technology. Siascopy is also embedded in its products Siametrics, Simsys and MoleMate, which MedX manufactures in its ISO 13485 certified facility. Siametrics, Simsys and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimetres beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration, and Conformite Europeenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil and Turkey.